Skip to main content
. Author manuscript; available in PMC: 2023 Feb 1.
Published in final edited form as: Lancet Oncol. 2022 Jan 12;23(2):292–303. doi: 10.1016/S1470-2045(21)00693-8

Figure 4: Forest plots for time to first deterioration (A) and time to confirmed deterioration (B) in FKSI-19 scores.

Figure 4:

This analysis includes all patients in the intention-to-treat population (nivolumab plus cabozantinib, n=323; sunitinib, n=328).

CI=confidence interval. DRS-P=disease-related symptoms-physical. DRSv1=disease-related symptoms version 1. EQ-5D-3L=three-level version of the EQ-5D. FKSI-19=Functional Assessment of Cancer Therapy-Kidney Symptom Index. FWB=functional wellbeing. IQR=interquartile range. NR=not reached. VAS=visual analogue scale.